Loading...

PODCAST

Base to Base Biotech

The Base to Base Biotech podcast is a weekly look at what"s happening in the world of biotech, with interviews with biotech leaders around the world.Whether it"s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.

health & fitness medicine

All Episodes

42:05

Base to Base biotech podcast 79: Fragile X syndrome...

Base to Base Biotech ·

2026/10/09

This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its Parkinson’s disease trial, and have a conversation with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Josep Prous, co-founder and chief scientific officer, about Fragile X syndrome.Times:03:15 Teitur Trophics14:03 CONNECTA TherapeuticsTeitur TrophicsTeitur Trophics recently announced successful results from its phase I clinical trial of its lead asset TT-P34 in

en

43:09

Base to Base biotech podcast 78: A new treatment for...

Base to Base Biotech ·

2026/10/02

This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment.Times:01:46 Dicot Pharma17:21 AllegroAllegroAllegro is a Belgium-based biomedical company which recently announced statistically significant improvements in pain and function in a 30-patient study of hydrocelin, a first-in-class nanotechnology injection

en

53:56

Base to Base biotech podcast 77: Transferring mammal...

Base to Base Biotech ·

2026/09/25

This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we chat with Lew Bender, CEO of Intensity Therapeutics, which is pioneering an intratumoral injection therapy primarily for breast cancer that not only kills the cancer cells in the tumour but throughout the body as well, acting as almost a cancer-killing vaccine.Times:04:22

en

53:41

Base to Base biotech podcast 76: Early disease...

Base to Base Biotech ·

2026/09/18

This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun Holt, CEO of Alveo Technologies, about the potential for animal diseases to jump to humans, and what we can do about it.Times:03:27 Cerenome28:27 Alveo TechnologiesCerenomeCerenome, formerly known as Plus Therapeutics, is a central nervous system (CNS) oncology company advancing an integrated platform that combines precision diagnostics, targeted

en

62:38

Base to Base biotech podcast 75: AI-powered...

Base to Base Biotech ·

2026/09/11

Times:03:17 Asgard Therapeutics32:43 WaivThis week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and we chat about clinical diagnostics with Meriem Sefta, CEO of Waiv.Asgard TherapeuticsAsgard Therapeutics is a biotech pioneering in vivo direct cell reprogramming for cancer immunotherapy.Asgard is using an innovative approach to force tumour cells to present their antigens to the

en

61:09

Base to Base biotech podcast 74: A vision for vision,...

Base to Base Biotech ·

2026/09/04

This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell Medical School, and William Matsui, the study's senior author and former executive vice dean for research at Dell Medical School; and Theialife president and CEO, Thomas Ruggia, about myopia.02:26 Theialife27:38 University of TexasTheialifeTheialife is a global ophthalmology drug development company focused on advancing first-in-class therapies that aim to address major unmet needs

en

50:49

Base to Base biotech podcast 73: Polymacrocyclic...

Base to Base Biotech ·

2026/08/28

This week, our guests are chief scientific officer of Valo Health, Karin Conde-Knape, and Karsten Eastman, CEO of Sethera Therapeutics.Times:03:06 Sethera Therapeutics20:08 Valo HealthValo HealthOur guest from Valo Health is chief scientific officer Karin Conde-Knape. As head of global drug discovery at Novo Nordisk, she helped expand the company’s research pipeline to more than 100 programmes across new therapeutic areas, including cardiovascular and liver diseases. Earlier this year, she joined

en

35:40

Base to Base biotech podcast 72: Cell-free DNA...

Base to Base Biotech ·

2026/08/21

This week, we have a conversation about the Flexible Automation for Scalable Health (FLASH) programme, focused on the development of scalable cell-free DNA bioproduction capabilities. Our guests are John Schiel, program manager at ARPA-H; DNA Script co-founder and CTO, Xavier Godron; and John Nelson, senior biosciences principal and FLASH program lead at GE HealthCare’s Healthcare Technology and Innovation Center.$26m ARPA-H funding for cell-free DNA bioproductionDNA Script and prime awardee GE

en

27:14

Base to Base biotech podcast 71: The IgA/CD89 axis

Base to Base Biotech ·

2026/08/14

This week, we have a conversation Paweł Szczepański, CEO of JJP Biologics about specially-built antibodies to tackle autoimmune diseases and cancer.JJP BiologicsJJP Biologics is a clinical-stage biotech that leverages its in-depth understanding of immune pathway science in autoimmune diseases and cancer. Starting from deep mechanistic insights, JJPBio engineers antibodies that are built-to-order, designed to restore immune balance and deliver better disease control for patients with significant

en

32:02

Base to Base biotech podcast 70: Taking the lead on...

Base to Base Biotech ·

2026/07/31

This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders.RenexxionRenexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders.Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.Dr. Falk Pharma

en

53:58

Base to Base biotech podcast 69: nrHSV-1 technology...

Base to Base Biotech ·

2026/07/24

Times:01:33 Cyllene Tx21:37 LinusBioThis week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx).Cyllene TherapeuticsCyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity

en

27:07

Base to Base biotech podcast 68: Water from air for...

Base to Base Biotech ·

2026/07/17

This week, we have a conversation with Kyle Cordova, founder and CEO of AquaPoro.AquaPoroAquaPoro is a deeptech company engineering systems that can harvest water from the atmosphere based in California that was spun out of Jordan's Royal Scientific Society. Atmospheric water generators (AWGs) aren't uncommon as freshwater becomes scarcer for use in a variety of industries from food and beverages to pharmaceutical companies.AquaPoro's approach is different. Traditional AWGs require more than 60%

en

45:37

Base to Base biotech podcast 67: Synthetic DNA and...

Base to Base Biotech ·

2026/07/10

Times:02:58 Deep Science Ventures22:16 4basebioThis week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures.4basebio4basebio is a UK-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines.Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the

en

60:42

Base to Base biotech podcast 66: The future of...

Base to Base Biotech ·

2026/07/03

This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida.Times:03:03 Longhorn Vaccines and Diagnostics25:03 LuvidaLonghorn Vaccines & Diagnostics on breakthroughs in molecular testingMaryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vaccines, monoclonal antibodies, and diagnostics targeting pathogens.The company focuses on innovative

en

26:46

Base to Base biotech podcast 65: Giving medicine a...

Base to Base Biotech ·

2026/06/26

This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold.Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round.The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequence design infrastructure- is engineered to overcome the biological

en

23:43

Base to Base biotech podcast 64: Solving logistics...

Base to Base Biotech ·

2026/06/19

This week, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus.Bora PharmaceuticalsBora Pharmaceuticals is an international contract development and manufacturing organization (CDMO) specialising in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products.With sites in North America and Asia, they deliver drug products to more

en

48:54

Base to Base biotech podcast 63: Cell and gene...

Base to Base Biotech ·

2026/06/12

This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics.Times:03:22 Cryoport Systems22:24 Kenai TherapeuticsCryoport SystemsCryoport Systems provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials used in biopharma development, reproductive medicine and animal health. Its services

en

26:14

Base to Base biotech podcast 62: A new approach to...

Base to Base Biotech ·

2026/06/05

This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.RevalesioWhile the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics.Revalesio is also focusing on stroke, a condition in need of new therapies.Revalesio’s breakthrough therapy, RNS60, is unlike traditional treatments. It uses a proprietary process to

en

61:08

Base to Base biotech podcast 61: Making tumours...

Base to Base Biotech ·

2026/05/29

This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology.Times:03:23 Kazia Therapeutics31:56 PureTech HealthPureTech HealthPureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value.The company recently announced positive topline data from its phase 1b clinical trial

en

24:43

Base to Base biotech podcast 60: Delivery method...

Base to Base Biotech ·

2026/05/22

This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster.Alessa TherapeuticsAlessa Therapeutics recently announced positive preliminary phase 1 safety and efficacy data for its prostate cancer treatment Enolen.This was the first study to demonstrate that the FDA-approved prostate cancer compound enzalutamide can be safely and locally administered to the prostate via sustained drug eluting implants.Recent key data presented by

en

79 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

Optimal Health Daily - Fitness and Nutrition

Optimal Living Daily | Dr. Neal Malik

Muscles by Brussels Radio

Dani Taylor